Fig. 2: Efficacy of microbial tumour neoantigen vaccines in primary and metastatic colorectal carcinoma.
From: Probiotic neoantigen delivery vectors for precision cancer immunotherapy
a–e, BALB/c mice with hind-flank CT26 tumours treated when average tumour volumes were 120–200 mm3. a, Intratumoural (i.t.) treatment on day 0. Tumour growth curves (n = 5 mice for PBS and EcNcΔlon/ΔompT NC, n = 7 for other groups, *P = 0.0469, **P = 0.0096, ****P < 0.0001; NS, P > 0.05, two-way ANOVA with Tukey’s multiple comparisons test). b, Intratumoural treatment. Intratumoural IL-12p70 levels (n = 6 mice per group, ***P = 0.0004, ****P < 0.0001; NS, P > 0.05, one-way ANOVA with Tukey’s multiple comparisons test). c, Intravenous (i.v.) treatment on day 0 and day 8. Tumour growth curves (n = 9 mice for nAg19, n = 8 for other groups, ****P < 0.0001; NS, P > 0.05, two-way ANOVA with Tukey’s multiple comparisons test). d, Mice (n = 5) received intravenous injection of EcNcΔlon/ΔompT/LLO+. Microbial tissue burden in CFU per gram (CFU g−1), LOD = 1 × 103 CFU g−1. e, Intravenous treatment of microbial therapies or PBS, or subcutaneous injections of SLP vaccine every 3–6 days. Tumour growth curves (n = 8 mice per group, ****P < 0.0001; NS, P > 0.05, two-way ANOVA with Tukey’s multiple comparisons test), f–h, BALB/c mice with 4 day established CT26-Luc lung metastases. Intravenous treatment every 3–5 days. f, Representative lung metastases luminescence. g, Mean total flux from lung metastases (n = 5 mice per group, ****P > 0.0001; NS, P > 0.05, two-way ANOVA with Dunnett’s multiple comparisons test). h, Kaplan–Meier survival curve for mice with CT26-Luc lung metastases (n = 5 mice per group, **P = 0.0017, **P = 0.0018, log-rank Mantel–Cox test). a–e,g, Data are mean ± s.e.m. s.c., subcutaneous. CR, complete response.
